Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a cutting-edge biotechnology company dedicated to the development of engineered cells as medicines to treat various diseases. Sana's primary focus is on cell and gene therapy, aiming to harness the potential of engineered cells to bring about transformative changes in healthcare.
The company is advancing a range of innovative therapeutic programs across multiple indications with unmet medical needs. Some of the key areas of focus include oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system (CNS) disorders. Sana's pipeline includes promising candidates such as SC291, SC262, SC255, and UP421, which are at various stages of development.
Recent Achievements and Projects:
- Hypoimmune Technology: Sana's proprietary hypoimmune (HIP) platform is designed to create cells that can evade the patient’s immune system, allowing for the transplant of allogeneic cells without the need for immunosuppression.
- CAR T Cell Therapies: The company is developing novel CAR T cell therapies for various cancers and autoimmune diseases. Preclinical data have shown that HIP-modified CAR T cells can avoid immune detection while retaining their functionality and anti-tumor effects.
- Pluripotent Stem Cells: Sana is also focused on differentiating pluripotent stem cells ex vivo into immune-cloaked functional cells, aiming to replace any missing or damaged cells in the body.
- Preclinical and Clinical Studies: In recent studies, Sana has demonstrated significant progress, such as the successful evasion of immune detection by HIP-modified CAR T cells and the potential for HIP-modified pancreatic islet cells to achieve insulin independence in diabetic models.
- Partnerships: The company collaborates with leading research institutions and organizations to further its mission of developing next-generation cell and gene therapies.
Sana Biotechnology operates out of multiple locations, including Seattle, Cambridge, South San Francisco, and Rochester, and is committed to advancing its pipeline of therapies to address critical healthcare challenges.
Rhea-AI Summary
Sana Biotechnology, Inc. (Nasdaq: SANA) has announced the pricing of its upsized public offering of 17,272,728 shares of common stock at $5.50 per share and pre-funded warrants to purchase 12,727,272 shares at $5.4999 per pre-funded warrant. The company has also granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. has announced an underwritten public offering of $125.0 million of shares of its common stock, with the intention to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) has received FDA clearance to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, particularly those who have received prior CD19-directed CAR T therapy. The company aims to address the significant unmet need for patients who have failed CD19-directed CAR T therapy by introducing SC262, which has shown durable complete responses in a substantial number of patients in the relapse setting. Sana has received three IND regulatory clearances and supported the authorization of an investigator-sponsored CTA to begin new studies utilizing their hypoimmune platform in seven different indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes. The company is expected to disclose initial proof of concept data for SC262 in 2024, presenting data from all of their studies this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will include a business overview and update by Steve Harr, Sana’s President and CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Sana Biotechnology, a company listed as NASDAQ: SANA, announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology at the 65th American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
Rhea-AI Summary
Sana Biotechnology, a company focused on engineered cells, announced the publication in Blood of initial clinical data from the ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
Rhea-AI Summary
Sana Biotechnology, Inc. (SANA) will present at two investor conferences in November and December, featuring a business overview and update. The company will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, and at the JMP Securities Hematology and Oncology Summit on December 6, 2023. Webcasts will be accessible on Sana's Investor Relations page with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) and Uppsala University Hospital in Sweden have announced the authorization of Uppsala University’s Clinical Trial Application (CTA) to initiate a first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes. The goal is to provide proof of concept for transplanting functional islet cells without immunosuppression. The study will focus on safety, cell survival, immune evasion, and C-peptide production. Insights from this study may inform the development of Sana’s SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) receives FDA clearance for Phase 1 trial of SC291, a CAR T cell therapy for multiple B-cell mediated autoimmune diseases. Initial clinical data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) reported financial results and business highlights for the third quarter 2023. The company is focusing on developing hypoimmune technology, with potential data from four clinical settings in 2023 and 2024. They are enrolling patients for Phase 1 ARDENT trial investigating SC291 in refractory B-cell malignancies, submitting CTA for IST evaluating HIP-modified primary islet cells in type 1 diabetes patients, and expecting proof of concept data for SC291 in multiple B-cell-mediated autoimmune diseases in 2024. Additionally, they are presenting multiple abstracts at the 2023 ASH Annual Meeting and have a cash position of $268.6 million expected to last into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
The current stock price of Sana Biotechnology (SANA) is $1.65 as of December 20, 2024.
What is the market cap of Sana Biotechnology (SANA)?
The market cap of Sana Biotechnology (SANA) is approximately 357.2M.
What does Sana Biotechnology, Inc. do?
Sana Biotechnology develops engineered cells as medicines and therapies to treat a wide range of diseases, including cancer, diabetes, and autoimmune disorders.
What is the company's primary focus?
Sana focuses on cell and gene therapy, leveraging proprietary technologies to create transformative treatments for unmet medical needs.
What is the hypoimmune (HIP) platform?
The HIP platform is designed to create cells that can evade the patient's immune system, allowing for the transplant of allogeneic cells without the need for immunosuppression.
What are some of Sana's key therapeutic areas?
Sana's key therapeutic areas include oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system (CNS) disorders.
What recent achievements has Sana Biotechnology made?
Recent achievements include preclinical data showing the immune evasion and anti-tumor effects of HIP-modified CAR T cells, and progress with stem cell-derived pancreatic islet cells for treating diabetes.
Where is Sana Biotechnology located?
Sana Biotechnology operates in Seattle, Cambridge, South San Francisco, and Rochester.
What is SC262?
SC262 is a hypoimmune, CD22-directed allogeneic CAR T cell therapy aimed at treating B-cell malignancies in patients who have failed previous CD19-directed therapies.
What is the significance of the hypoimmune platform?
The hypoimmune platform allows for the creation of allogeneic cells that can evade immune detection, potentially enabling sustained therapeutic effects without the need for immunosuppression.
How is Sana Biotechnology advancing its CAR T cell therapies?
Sana is developing CAR T cell therapies for cancers and autoimmune diseases, with promising preclinical data showing sustained immune evasion and anti-tumor effects.
How can I find more information about Sana Biotechnology?
For more information, please visit the company's official website at https://sana.com/.
Sana Biotechnology, Inc.
Nasdaq:SANA
SANA Rankings
SANA Stock Data
357.23M
203.42M
8.63%
92.47%
15.84%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
SEATTLE